Imatinib mesylate in the treatment of Core Binding Factor leukemias with KIT mutations

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

Yongsheng Ma, Shan Zeng, Dean D. Metcalfe et al. · Blood · 2002 · 448 citations · Full text

Life Sciences, Genetics, Molecular Biology +16

C-kit mutations in core binding factor leukemias

Alessandro Beghini, Paolo Peterlongo, Carla B. Ripamonti et al. · Blood · 2000 · 299 citations · Full text

Medicine, Molecular Biology, Oncology +14

c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia

Mamdooh Gari, Anne Goodeve, Gill Wilson et al. · British Journal of Haematology · 1999 · 264 citations

Medicine, Genetics, Molecular Genetics +17

KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication.

Alessandro Beghini, Carla B. Ripamonti, Roberto Cairoli et al. · PubMed · 2004 · 162 citations

Life Sciences, Genetics, Hematology +17

Efficacy and safety of imatinib in adult patients with c-kit–positive acute myeloid leukemia

Thomas Kindler, Frank Breitenbuecher, Andreas Marx et al. · Blood · 2004 · 135 citations · Full text

Medicine, Hematology, Oncology +6